6 research outputs found
Crystal Structure of a Human K‑Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d
The Ras proteins
play roles in cell differentiation, proliferation,
and survival. Aberrant signaling through Ras-mediated pathways in
tumor cells occurs as a result of several types of mutational damage,
which most frequently affects the amino acids G12, G13, and Q61. Recently,
KRpep-2d was identified as a K-RasÂ(G12D) selective inhibitory peptide
against the G12D mutant of K-Ras, which is a key member of the Ras
protein family and an attractive cancer therapeutic target. In this
study, the crystal structure of the human K-RasÂ(G12D) mutant was determined
in complex with GDP and KRpep-2d at 1.25 Ă… resolution. This structure
revealed that the peptide binds near Switch II and allosterically
blocks protein–protein interactions with the guanine nucleotide
exchange factor. This discovery of a unique binding pocket provides
valuable information that will facilitate the design of direct Ras
inhibitors
Second-Generation AUTACs for Targeted Autophagic Degradation
Targeted protein degradation via the ubiquitin-proteasome
system
has emerged as one of the most promising drug discovery modalities.
Autophagy, another intracellular degradation system, can target a
wide range of nonproteinous substrates as well as proteins, but its
application to targeted degradation is still in its infancy. Our previous
work revealed a relationship between guanine modification of cysteine
residues on intracellular proteins and selective autophagy, resulting
in the first autophagy-based degraders, autophagy-targeted chimeras
(AUTACs). Based on the research background, all the reported AUTACs
compounds contain cysteine as a substructure. Here, we examine the
importance of this substructure by conducting SAR studies and report
significant improvements in the degrader’s activity by replacing
cysteine with other moieties. Several derivatives showed sub-ÎĽM
range degrading activity, demonstrating the increased practical value
of AUTACs
Second-Generation AUTACs for Targeted Autophagic Degradation
Targeted protein degradation via the ubiquitin-proteasome
system
has emerged as one of the most promising drug discovery modalities.
Autophagy, another intracellular degradation system, can target a
wide range of nonproteinous substrates as well as proteins, but its
application to targeted degradation is still in its infancy. Our previous
work revealed a relationship between guanine modification of cysteine
residues on intracellular proteins and selective autophagy, resulting
in the first autophagy-based degraders, autophagy-targeted chimeras
(AUTACs). Based on the research background, all the reported AUTACs
compounds contain cysteine as a substructure. Here, we examine the
importance of this substructure by conducting SAR studies and report
significant improvements in the degrader’s activity by replacing
cysteine with other moieties. Several derivatives showed sub-ÎĽM
range degrading activity, demonstrating the increased practical value
of AUTACs
Discovery of a Novel Series of <i>N</i>‑Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase‑2 Inhibitors
Acyl
CoA:monoacylglycerol acyltransferase-2 (MGAT2) has attracted
interest as a novel target for the treatment of obesity and metabolic
diseases. Starting from <i>N</i>-phenylbenzenesulfonamide
derivative <b>1</b> with moderate potency for MGAT2 inhibition,
we explored an effective location of the hydrophobic group at the
1-position to enhance MGAT2 inhibitory activity. Shifting the hydrophobic
group to the adjacent position followed by introduction of a bicyclic
central core to restrict the substituent orientation produced <i>N</i>-phenylindoline-5-sulfonamide derivative <b>10b</b>, which displayed much improved potency, with an IC<sub>50</sub> value
of 1.0 nM. This compound also exhibited excellent selectivity (greater
than 30,000-fold) against related acyltransferases (MGAT3, DGAT1,
DGAT2, and ACAT1). Subsequent optimization efforts were directed toward
improving pharmacokinetic profiles, which resulted in the identification
of 5-[(2,4-difluorophenyl)Âsulfamoyl]-7-(2-oxopyrrolidin-1-yl)-<i>N</i>-[4-(trifluoromethyl)Âphenyl]-2,3-dihydro-1<i>H</i>-indole-1-carboxamide (<b>24d</b>) endowed with potent MGAT2
inhibitory activity (IC<sub>50</sub> = 3.4 nM) and high oral bioavailability
(<i>F</i> = 52%, mouse). In a mouse oral fat tolerance test,
oral administration of this compound effectively suppressed the elevation
of plasma triacylglycerol levels
Discovery of Novel 5‑(Piperazine-1-carbonyl)pyridin-2(1<i>H</i>)‑one Derivatives as Orally eIF4A3-Selective Inhibitors
Starting
from our previous eIF4A3-selective inhibitor <b>1a</b>, a novel
series of (piperazine-1-carbonyl)Âpyridin-2Â(1<i>H</i>)-one
derivatives was designed, synthesized, and evaluated for identification
of orally bioavailable probe molecules. Compounds <b>1o</b> and <b>1q</b> showed improved physicochemical and ADMET profiles, while
maintaining potent and subtype-selective eIF4A3 inhibitory potency.
In accord with their promising PK profiles and results from initial
in vivo PD studies, compounds <b>1o</b> and <b>1q</b> showed
antitumor efficacy with T/C values of 54% and 29%, respectively, without
severe body weight loss. Thus, our novel series of compounds represents
promising probe molecules for the in vivo pharmacological study of
selective eIF4A3 inhibition
Synthesis, Structure–Activity Relationship, and Pharmacological Studies of Novel Melanin-Concentrating Hormone Receptor 1 Antagonists 3-Aminomethylquinolines: Reducing Human Ether-a-go-go-Related Gene (hERG) Associated Liabilities
Recently, we discovered 3-aminomethylquinoline derivative <b>1</b>, a selective, highly potent, centrally acting, and orally
bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited
food intake in F344 rats with diet-induced obesity (DIO). Subsequent
investigation of <b>1</b> was discontinued because <b>1</b> showed potent hERG K<sup>+</sup> channel inhibition in a patch-clamp
study. To decrease hERG K<sup>+</sup> channel inhibition, experiments
with ligand-based drug designs based on <b>1</b> and a docking
study were conducted. Replacement of the terminal <i>p</i>-fluorophenyl group with a cyclopropylmethoxy group, methyl group
introduction on the benzylic carbon at the 3-position of the quinoline
core, and employment of a [2-(acetylamino)Âethyl]Âamino group as the
amine portion eliminated hERG K<sup>+</sup> channel inhibitory activity
in a patch-clamp study, leading to the discovery of <i>N</i>-{3-[(1<i>R</i>)-1-{[2-(acetylamino)Âethyl]Âamino}Âethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)Âbenzamide <b>(</b><i><b>R</b></i><b>)-10h</b>. The compound <b>(</b><i><b>R</b></i><b>)-10h</b> showed
potent inhibitory activity against hMCHR1 and dose-dependently suppressed
food intake in a 2-day study on DIO-F344 rats. Furthermore, practical
chiral synthesis of <b>(</b><i><b>R</b></i><b>)-10h</b> was performed to determine the molecule’s absolute
configuration